Calcitonin receptor (CALCR)
Lee S, et al
54 Via a peripheral mechanism, this is thought to contribute to lower insulin sensitivity and the development of insulin resistance
The primary antibodies used included anti-ZO-1 (Abcam, ab307799, 1:5000), anti-Occludin (Abcam, ab216327, 1:5000), anti-ACSL4 (Abcam, ab155282, 1:10000), anti-TFR1 (ABclonal, A5865, 1:2000), anti-SLC7 A11 (Abcam, ab175186, 1:5000), anti-GPX4 (Abcam, ab125066, 1:5000), anti-VDAC2 (Proteintech, 116631-AP, 1:5000), anti-VDAC3 (Proteintech, 552601-AP, 1:5000), -tubulin (Proteintech, 100681-AP, 1:5000), and GAPDH (Proteintech, 104941-AP, 1:20000)
Oral administration demonstrates activity in gastrointestinal conditions despite lower systemic bioavailability, as direct mucosal exposure may contribute to therapeutic effects